Base Editing Therapy tBE Achieves Durable Remission in Sickle Cell Disease and Beta-Thalassemia
A new study published in Cell Stem Cell confirms that tBE-mediated base editing therapy has achieved durable clinical remission in patients with sickle cell disease and beta-thalassemia. The therapy demonstrated safety and efficacy across different genetic backgrounds.
Shanghai, China – September 7, 2026 – New findings on the efficacy and safety of tBE-mediated base editing therapy for sickle cell disease (SCD) and beta-thalassemia (TDT) have been published in the journal Cell Stem Cell. The study reports that the therapy has achieved durable clinical remission in patients representing diverse genetic backgrounds.
Building upon earlier results from China where TDT patients achieved 100% transfusion independence, this latest research confirms that tBE therapy is equally safe and effective for SCD patients of African descent and TDT patients from South and Southeast Asia. This broadens the potential applicability of the therapy globally.
The therapy utilizes a base editing technology known as tBE, which precisely targets specific DNA sequences. This precision is believed to be key to achieving sustained clinical responses and improving transfusion independence. The study specifically investigated the impact of varying genetic backgrounds on treatment outcomes.
These findings suggest that tBE technology may offer a new therapeutic avenue for inherited blood disorders, which represent a significant global health burden. Further research is anticipated to confirm long-term effects and gather data from a wider patient cohort.